Drug intelligence / Profile preview

Lumi804-Anti-LHRH

Development stage: Preclinical
Lead developer: Lumiphore
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Lumi804-Anti-LHRH is a preclinical-stage radiotheranostic agent developed by Lumiphore for the imaging and treatment of tumors expressing the Luteinizing Hormone-Releasing Hormone (LHRH) receptor, primarily prostate cancer. The asset utilizes Lumiphore's proprietary Lumi804™ macrocyclic BiFunctional Chelate (mBFC) technology to conjugate a targeting antibody against LHRH with radioisotopes. As a theranostic pair, it can be labeled with Zirconium-89 (89Zr) for positron emission tomography (PET) imaging to identify LHRH-positive lesions, or with Lutetium-177 (177Lu) for targeted beta-emitting radiotherapy. This approach aims to provide a personalized treatment pathway by visualizing the target before delivering therapeutic radiation directly to the cancer cells.

Other names: Lumi804 Anti-LHRH radiotheranosticLumi-804 Anti-LHRH radiotheranosticLumi 804 Anti-LHRH radiotheranostic

Targets

GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on Lumi804-Anti-LHRH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lumi804-Anti-LHRH.

Explore the full profile